摘要
目的 评价骨髓间充质干细胞（BM-MSC）移植对难治型PBC患者的免疫调节作用.方法 对10例对熊去氧胆酸（UDCA）生化应答不良的难治型PBC患者行BM-MSC移植后,以配对样本t检验方法评价观察治疗后第1、3、6、12个月的外周血细胞因子及淋巴细胞亚群的变化.结果 ①经BM-MSC移植,受试者外周血CD8^＋T细胞比例下降[治疗前（16.8±2.4）％与治疗3个月时（11.2±1.9）％,t=3.04,P=0.014;治疗前（16.8±2.4）％与治疗6个月时（10.1±1.7）％,t=4.79,P=0.001],差异有统计学意义;②BM-MSC移植治疗后,CD4^＋CD25^＋Foxp3^＋T细胞比例升高[治疗前（0.44±0.11）％与治疗6个月时（1.23±0.25）％,t=-2.711,P=0.030],差异有统计学意义;③BM-MSC移植治疗可使受试者外周血IL-10浓度升高[治疗前（1.83±0.23） pg/ml与治疗3个月时（2.67±0.28） pg/ml,t=-4.062,P=0.004],差异有统计学意义.结论 BM-MSC可能通过下调PBC患者外周血CD8^＋T细胞,上调CD4^＋CD25^＋Foxp3^＋T细胞和升高外周血IL-10浓度来实现对PBC患者的体内免疫调节作用.
Objective To evaluate the immunodulatory effect of bone marrow mesenchymal stem cells （BM-MSC） in refractory primary biliary cirrhosis （PBC）.Methods Ten UDCA-resistant PBC patients who accepted BM-MSC transplantation were enrolled into this study.The changes of cytokines and lymphocyte subtypes were analyzed during the follow-up by paired samples t test.Results ① BM-MSC transplantation decreased the percentage of CD8^＋ T cells of PBC patients [3 months after transplantation,（16.8 ±2.4）% vs （11.2± 1.9）%,t=3.04,P=0.014; 6 months after transplantation,（16.8±2.4）% vs （10.1 ± 1.7）%,t=4.79,P=0.001].② By BM-MSC transplantation,the percentage of CD4^＋CD25^＋Foxp3^＋ T cell in peripheral lymphocytic subsets was raised [6 months after transplantation,（0.44±0.11）% vs （1.23±0.25）%,t=-2.711,P=0.030].③ BM-MSC could elevate the serum level of IL-10 [3 months after transplantation,pg/nl,1.83±0.23 vs 2.67±0.28,t=-4.062,P=0.004].Conclusion The important immunoregulatory role of immigrated BM-MSC in PBC probably attribute to the upgrade of CD4^＋CD25^＋Foxp3^＋ T cells and IL-10 and downgrade of CD8^＋ T Cells.
出处
《中华风湿病学杂志》
CAS
CSCD
北大核心
2014年第12期798-801,共4页
Chinese Journal of Rheumatology
基金
国家高技术研究发展计划（863计划）（2011AA020-111）
“重大新药创制”科技重大专项（2012ZX093.03006-002）
卫生公益性行业科研专项（201202004）
